Build an autoimmune hepatitis diagnosis from concordant evidence, interpret interface injury, and plan induction, sustained remission, and relapse care.
A positive ANA is a reason to investigate, not a prescription for prednisone. Autoimmune hepatitis becomes convincing when the injury pattern, IgG, antibodies, biopsy, and exclusion of competing causes tell a coherent story. The next decision is whether the patient has stable inflammatory disease or failing liver function.
Build the diagnosis from independent evidence
Autoimmune hepatitis is immune-mediated inflammation directed at the liver in a susceptible person. It can present as unexplained laboratory abnormalities, fatigue and arthralgia, jaundice, cirrhosis, or acute liver failure. Although more common in women, it occurs across ages and sexes. Neither an older man nor a child should be excluded by a demographic shortcut. Associated thyroid disease, celiac disease, or another autoimmune disorder raises suspicion without establishing the hepatic diagnosis. [1]
The usual biochemical pattern is hepatocellular, with aminotransferases predominating. IgG is often increased polyclonally. Albumin, bilirubin, INR, platelets, and the examination help assess reserve and chronicity. Mild ALP elevation is compatible with AIH. A disproportionate cholestatic pattern should prompt investigation for a cholangiopathy or variant phenotype rather than being forced into pure AIH.
ANA and smooth muscle antibodies
ANA and SMA, also called ASMA, support the common historical type 1 pattern. They can also occur in healthy people and in other liver diseases, including metabolic dysfunction-associated steatotic liver disease. A positive result alone is not specific enough to diagnose AIH.
LKM1 and LC1 antibodies
Anti-liver kidney microsomal type 1 and anti-liver cytosol type 1 reactivity is particularly associated with younger pediatric presentations. Hepatitis C can complicate interpretation of LKM reactivity. Historical type 2 terminology may appear in examinations, but EASL 2025 does not recommend antibody-based subclassification to determine treatment.
IgG and additional antibodies
High IgG strengthens the pattern and helps monitor response. Normal IgG, particularly in acute disease, does not exclude AIH. Negative ANA and SMA also do not end the evaluation. Additional testing such as anti-SLA/LP and expert biopsy interpretation may be useful when suspicion remains. [1][2]
Simplified diagnostic scores combine autoantibodies, IgG, histology, and exclusion of viral hepatitis. They organize evidence; they do not replace judgment in acute severe, seronegative, pediatric, or overlapping disease. Assay methods and thresholds matter. Do not transfer a titer cutoff between different laboratory methods without checking how the assay was validated. [1]
Locate the inflammatory injury on biopsy
The portal tract contains branches of the portal vein and hepatic artery and a bile duct within connective tissue. The limiting plate is the bordering layer of periportal hepatocytes, not a thick membrane or a separate duct. Interface hepatitis means inflammatory activity extends from the portal region into adjacent parenchyma with injury to those hepatocytes.
From portal tract to hepatic parenchyma. This conceptual arrangement shows relationships, not a scaled lobule.
Portal tract. Lymphocytes and plasma cells may accumulate around portal structures.
Limiting plate. The first bordering hepatocytes are injured where portal inflammation meets the parenchyma.
Periportal and lobular tissue. Interface and lobular hepatitis can coexist; more severe disease may produce confluent or bridging necrosis.
Repeated injury and repair. Fibrosis may extend between vascular regions, eventually distorting architecture into cirrhosis.
This is a spatial explanation with a possible long-term consequence, not a required sequence in every biopsy. Acute disease can have prominent lobular or centrilobular injury. [1]
Plasma cell enrichment supports AIH but is neither universal nor pathognomonic. Hepatocyte rosettes and emperipolesis, in which another cell is present within a hepatocyte, are historical descriptors. EASL 2025 no longer classifies them as typical AIH lesions because they lack specificity; they may instead reflect injury severity. A biopsy lacking rosettes does not exclude AIH. Conversely, a plasma-cell-rich biopsy does not make drug injury impossible. Read histology together with clinical timing and the exclusion workup. [1][2]
Biopsy also stages fibrosis and assesses activity. Bridging necrosis describes confluent cell loss linking regions; bridging fibrosis describes established scar. They are related through injury and repair but are not synonyms. Prominent destructive bile duct injury favors a biliary process or variant disease. Obtain biopsy before long-term immunosuppression when feasible. If coagulopathy makes a percutaneous approach unsafe, expert teams can consider an alternative approach such as transjugular sampling. Urgent stabilization or treatment must not be delayed simply to obtain a routine outpatient biopsy. [1]
Exclude the conditions that change treatment
Before committing to long-term immunosuppression, assess viral hepatitis, medications and supplements, alcohol exposure, steatotic liver disease, and age-appropriate metabolic causes. Wilson disease deserves attention in a young person with unexplained liver disease. A positive ANA should not stop a copper-related evaluation when the clinical presentation warrants one. Viral and autoimmune disease can coexist, so the workup should resolve competing explanations rather than choose whichever test returned first.
Minocycline and nitrofurantoin are recognized examples of drugs that can produce autoimmune-like hepatitis. The laboratory and biopsy findings may closely resemble idiopathic AIH. Stop a plausible culprit, document the exposure timeline, assess severity, and follow the course. Persistent or severe injury may still require glucocorticoids. Improvement and absence of later relapse after drug withdrawal support a drug-induced process, but this distinction may take time and is not guaranteed by one normal result. [1]
Cholestatic findings require a different branch of evaluation. Pruritus, marked ALP elevation, antimitochondrial antibodies, and destructive small-duct injury suggest primary biliary cholangitis. Inflammatory bowel disease and multifocal biliary strictures suggest primary sclerosing cholangitis. AIH-PBC and AIH-PSC variants can require treatment of both inflammatory components. Children with autoimmune liver disease deserve particular attention to sclerosing cholangitis. Do not treat a positive antibody as permission to ignore the biliary anatomy. [1]
Suppress active disease while planning maintenance
Induction aims to control active inflammation before it causes further loss of liver tissue. Prednisone or prednisolone supplies the initial glucocorticoid effect. A steroid-sparing partner allows control with less cumulative steroid exposure. For adults, EASL 2025 recommends predniso(lo)ne with either azathioprine or mycophenolate mofetil as first-line therapy. Pediatric regimens require pediatric hepatology guidance; the adult MMF recommendation should not be transferred automatically to children. Choice depends on severity, tolerance, cytopenias, reproductive plans, and local specialist practice. Mycophenolate is not restricted to rescue after azathioprine failure in this guidance. A randomized trial in treatment-naive adults supports its induction efficacy, but this does not make it suitable for every patient. [1][3]
Azathioprine
Azathioprine is not the sole immediate rescue drug for acute liver failure. Its use requires baseline blood counts and liver tests, assessment of thiopurine metabolism risk, and continued laboratory monitoring. TPMT testing helps identify patients vulnerable to severe myelosuppression; a normal result does not eliminate toxicity risk or replace CBC follow-up. Cytopenias, pancreatitis, and hepatotoxicity require reassessment. For adult induction, EASL recommends introducing azathioprine when bilirubin is below 6 mg/dL, ideally about two weeks after corticosteroids begin, with specialist assessment of severity and toxicity risk. [1][2]
Mycophenolate and budesonide
Mycophenolate is teratogenic and is contraindicated in pregnancy. Preconception planning requires a supervised transition to compatible therapy and the recommended washout and contraception interval. EASL advises stopping it at least three months before conception. Azathioprine and glucocorticoids may be continued when indicated during pregnancy under specialist care; abrupt withdrawal can allow a flare.
Budesonide has high hepatic first-pass clearance, which can reduce systemic exposure when normal liver circulation is preserved. Cirrhosis and shunting undermine that advantage. EASL 2025 does not recommend budesonide as first-line therapy and contraindicates it in cirrhosis. A selected noncirrhotic patient dependent on predniso(lo)ne with steroid adverse effects may be considered for a switch. This qualified option does not extend to acute liver failure. [1]
During glucocorticoid therapy, monitor glucose, blood pressure, weight, infection, sleep or mood effects, and bone health. Check immunization status and relevant infection risks before and during immunosuppression. Maintenance must control the disease and reduce avoidable treatment harm; it is not simply a smaller prescription with no follow-up.
Use laboratory response and liver function to choose the next step
Complete biochemical response means normalization of AST, ALT, and IgG. Symptom relief or a large percentage fall in ALT is not the same endpoint. EASL discusses the six-month response benchmark and recognizes that some patients respond by twelve months. Failure to normalize should trigger review of adherence, dose, diagnosis, drug toxicity, and other liver disease. It does not mean every stable partial responder needs an abrupt regimen change, and it never justifies waiting when function deteriorates. [1]
After response, taper glucocorticoids according to biochemistry and tolerability while maintaining an effective steroid-sparing regimen. Many patients need long-term, sometimes lifelong treatment. A withdrawal trial is reserved for carefully selected patients with stable complete response for at least two years on low-dose monotherapy. Two years of treatment with only recent normalization is not equivalent. Consider disease course, fibrosis, relapse history, patient preferences, and sometimes repeat biopsy. Even histologic remission does not guarantee permanent drug-free control.
Withdrawal is stepwise and followed by continued surveillance. EASL recommends relapse monitoring at least every three months in the first year. Its detailed withdrawal pathway checks aminotransferases and IgG every three to four weeks for the first three months, then every three months through year one, with continued individualized follow-up for late relapse. A confirmed relapse generally requires reinduction with a previously effective regimen and renewed long-term maintenance. First distinguish relapse from missed medication, drug injury, and infection. [1]
Rising INR, jaundice, hypoglycemia, or encephalopathy calls for urgent reassessment. Acute severe AIH with coagulopathy but without encephalopathy or acute-on-chronic liver failure may receive a closely monitored steroid trial; failure to improve within three to seven days should prompt transplant-center referral. AIH with acute liver failure warrants direct transplant-center discussion while treatment and infection surveillance continue. Do not wait months for azathioprine or mycophenolate to rescue failing function. Decompensated AIH cirrhosis also warrants transplant evaluation. [1][4]
Concordant evidence establishes the diagnosis. Normal AST, ALT, and IgG establish the biochemical target. Sustained control determines maintenance decisions. Worsening function determines urgency.
Make the diagnosis and treatment decision
Case 1
Show answer and explanations for case 1
A. Chronic viral hepatitis is the leading diagnosis (Why this does not fit)
The negative viral workup and concordant IgG, autoantibody and biopsy findings favor AIH over viral hepatitis.
B. The combined findings strongly support AIH (Best answer)
Serology, IgG, biopsy, and exclusion of mimics align.
C. Primary biliary cholangitis is the leading diagnosis (Why this does not fit)
The described injury is hepatocellular and interface-based, without the cholestatic or destructive duct evidence expected for PBC.
D. Steatotic liver disease alone is the leading diagnosis (Why this does not fit)
Steatosis is not described; high IgG and the integrated serologic and histologic findings support AIH.
Takeaway: Build the diagnosis from concordant evidence.
A. Maintain prednisolone because budesonide has no role in this setting (Why this does not fit)
EASL permits a selected switch for noncirrhotic patients with predniso(lo)ne dependence and adverse effects; maintaining the same regimen is not the only option.
B. A specialist-supervised switch to budesonide for this patient (Best answer)
EASL allows consideration in noncirrhotic predniso(lo)ne-dependent patients with adverse effects.
C. Switch to budesonide and discontinue the steroid-sparing drug (Why this does not fit)
Considering a different corticosteroid does not establish that the accompanying maintenance treatment is no longer needed.
D. Choose budesonide only if subsequent evaluation identifies cirrhosis (Why this does not fit)
Cirrhosis contraindicates budesonide. The selected switch discussed here requires its absence.
Takeaway: An optional selected switch is different from routine first-line treatment.
